We identified Aurora kinase B as a putative novel therapeutic target in fulvestrant and tamoxifen resistant breast cancer cells, and further explored its role in signaling and growth of fulvestrant resistant T47D cell lines by using the selective Aurora kinase B inhibitors, barasertib and hesperadin. This evidence concerns the gene AURKB and breast carcinoma.